Report cover image

Global ADHD Medication Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 192 Pages
SKU # APRC20359469

Description

Summary

According to APO Research, the global ADHD Medication market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for ADHD Medication is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for ADHD Medication is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the ADHD Medication market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for ADHD Medication is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the ADHD Medication market include Takeda, Johnson & Johnson, Novartis, Eli Lilly, Zhengda Fenghai, Tris Pharma, Inc, Purdue Parma, Noven Pharmaceuticals and Neos Therapeutics, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for ADHD Medication, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of ADHD Medication, also provides the value of main regions and countries. Of the upcoming market potential for ADHD Medication, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the ADHD Medication revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global ADHD Medication market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global ADHD Medication company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
ADHD Medication Segment by Company

Takeda
Johnson & Johnson
Novartis
Eli Lilly
Zhengda Fenghai
Tris Pharma, Inc
Purdue Parma
Noven Pharmaceuticals
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
ADHD Medication Segment by Type

Stimulant
Non-stimulant
ADHD Medication Segment by Application

Hyperactivity/impulse Control Disorder
Hybrid
Attention Deficit
ADHD Medication Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global ADHD Medication status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the ADHD Medication key companies, revenue, market share, and recent developments.
3. To split the ADHD Medication breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions ADHD Medication market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify ADHD Medication significant trends, drivers, influence factors in global and regions.
6. To analyze ADHD Medication competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADHD Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of ADHD Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADHD Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ADHD Medication industry.
Chapter 3: Detailed analysis of ADHD Medication company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of ADHD Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of ADHD Medication in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Global ADHD Medication Market Size, 2020 VS 2024 VS 2031
1.3 Global ADHD Medication Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ADHD Medication Market Dynamics
2.1 ADHD Medication Industry Trends
2.2 ADHD Medication Industry Drivers
2.3 ADHD Medication Industry Opportunities and Challenges
2.4 ADHD Medication Industry Restraints
3 ADHD Medication Market by Company
3.1 Global ADHD Medication Company Revenue Ranking in 2024
3.2 Global ADHD Medication Revenue by Company (2020-2025)
3.3 Global ADHD Medication Company Ranking (2023-2025)
3.4 Global ADHD Medication Company Manufacturing Base and Headquarters
3.5 Global ADHD Medication Company Product Type and Application
3.6 Global ADHD Medication Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global ADHD Medication Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 ADHD Medication Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 ADHD Medication Market by Type
4.1 ADHD Medication Type Introduction
4.1.1 Stimulant
4.1.2 Non-stimulant
4.2 Global ADHD Medication Sales Value by Type
4.2.1 Global ADHD Medication Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global ADHD Medication Sales Value by Type (2020-2031)
4.2.3 Global ADHD Medication Sales Value Share by Type (2020-2031)
5 ADHD Medication Market by Application
5.1 ADHD Medication Application Introduction
5.1.1 Hyperactivity/impulse Control Disorder
5.1.2 Hybrid
5.1.3 Attention Deficit
5.2 Global ADHD Medication Sales Value by Application
5.2.1 Global ADHD Medication Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global ADHD Medication Sales Value by Application (2020-2031)
5.2.3 Global ADHD Medication Sales Value Share by Application (2020-2031)
6 ADHD Medication Regional Value Analysis
6.1 Global ADHD Medication Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global ADHD Medication Sales Value by Region (2020-2031)
6.2.1 Global ADHD Medication Sales Value by Region: 2020-2025
6.2.2 Global ADHD Medication Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America ADHD Medication Sales Value (2020-2031)
6.3.2 North America ADHD Medication Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe ADHD Medication Sales Value (2020-2031)
6.4.2 Europe ADHD Medication Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific ADHD Medication Sales Value (2020-2031)
6.5.2 Asia-Pacific ADHD Medication Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America ADHD Medication Sales Value (2020-2031)
6.6.2 South America ADHD Medication Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa ADHD Medication Sales Value (2020-2031)
6.7.2 Middle East & Africa ADHD Medication Sales Value Share by Country, 2024 VS 2031
7 ADHD Medication Country-level Value Analysis
7.1 Global ADHD Medication Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global ADHD Medication Sales Value by Country (2020-2031)
7.2.1 Global ADHD Medication Sales Value by Country (2020-2025)
7.2.2 Global ADHD Medication Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA ADHD Medication Sales Value Growth Rate (2020-2031)
7.3.2 USA ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.3.3 USA ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada ADHD Medication Sales Value Growth Rate (2020-2031)
7.4.2 Canada ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico ADHD Medication Sales Value Growth Rate (2020-2031)
7.5.2 Mexico ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany ADHD Medication Sales Value Growth Rate (2020-2031)
7.6.2 Germany ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France ADHD Medication Sales Value Growth Rate (2020-2031)
7.7.2 France ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.7.3 France ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. ADHD Medication Sales Value Growth Rate (2020-2031)
7.8.2 U.K. ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy ADHD Medication Sales Value Growth Rate (2020-2031)
7.9.2 Italy ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain ADHD Medication Sales Value Growth Rate (2020-2031)
7.10.2 Spain ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia ADHD Medication Sales Value Growth Rate (2020-2031)
7.11.2 Russia ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands ADHD Medication Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries ADHD Medication Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China ADHD Medication Sales Value Growth Rate (2020-2031)
7.14.2 China ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.14.3 China ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan ADHD Medication Sales Value Growth Rate (2020-2031)
7.15.2 Japan ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea ADHD Medication Sales Value Growth Rate (2020-2031)
7.16.2 South Korea ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India ADHD Medication Sales Value Growth Rate (2020-2031)
7.17.2 India ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.17.3 India ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia ADHD Medication Sales Value Growth Rate (2020-2031)
7.18.2 Australia ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia ADHD Medication Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil ADHD Medication Sales Value Growth Rate (2020-2031)
7.20.2 Brazil ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina ADHD Medication Sales Value Growth Rate (2020-2031)
7.21.2 Argentina ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile ADHD Medication Sales Value Growth Rate (2020-2031)
7.22.2 Chile ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia ADHD Medication Sales Value Growth Rate (2020-2031)
7.23.2 Colombia ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru ADHD Medication Sales Value Growth Rate (2020-2031)
7.24.2 Peru ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia ADHD Medication Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel ADHD Medication Sales Value Growth Rate (2020-2031)
7.26.2 Israel ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE ADHD Medication Sales Value Growth Rate (2020-2031)
7.27.2 UAE ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey ADHD Medication Sales Value Growth Rate (2020-2031)
7.28.2 Turkey ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran ADHD Medication Sales Value Growth Rate (2020-2031)
7.29.2 Iran ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran ADHD Medication Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt ADHD Medication Sales Value Growth Rate (2020-2031)
7.30.2 Egypt ADHD Medication Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt ADHD Medication Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Takeda
8.1.1 Takeda Comapny Information
8.1.2 Takeda Business Overview
8.1.3 Takeda ADHD Medication Revenue and Gross Margin (2020-2025)
8.1.4 Takeda ADHD Medication Product Portfolio
8.1.5 Takeda Recent Developments
8.2 Johnson & Johnson
8.2.1 Johnson & Johnson Comapny Information
8.2.2 Johnson & Johnson Business Overview
8.2.3 Johnson & Johnson ADHD Medication Revenue and Gross Margin (2020-2025)
8.2.4 Johnson & Johnson ADHD Medication Product Portfolio
8.2.5 Johnson & Johnson Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis ADHD Medication Revenue and Gross Margin (2020-2025)
8.3.4 Novartis ADHD Medication Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Eli Lilly
8.4.1 Eli Lilly Comapny Information
8.4.2 Eli Lilly Business Overview
8.4.3 Eli Lilly ADHD Medication Revenue and Gross Margin (2020-2025)
8.4.4 Eli Lilly ADHD Medication Product Portfolio
8.4.5 Eli Lilly Recent Developments
8.5 Zhengda Fenghai
8.5.1 Zhengda Fenghai Comapny Information
8.5.2 Zhengda Fenghai Business Overview
8.5.3 Zhengda Fenghai ADHD Medication Revenue and Gross Margin (2020-2025)
8.5.4 Zhengda Fenghai ADHD Medication Product Portfolio
8.5.5 Zhengda Fenghai Recent Developments
8.6 Tris Pharma, Inc
8.6.1 Tris Pharma, Inc Comapny Information
8.6.2 Tris Pharma, Inc Business Overview
8.6.3 Tris Pharma, Inc ADHD Medication Revenue and Gross Margin (2020-2025)
8.6.4 Tris Pharma, Inc ADHD Medication Product Portfolio
8.6.5 Tris Pharma, Inc Recent Developments
8.7 Purdue Parma
8.7.1 Purdue Parma Comapny Information
8.7.2 Purdue Parma Business Overview
8.7.3 Purdue Parma ADHD Medication Revenue and Gross Margin (2020-2025)
8.7.4 Purdue Parma ADHD Medication Product Portfolio
8.7.5 Purdue Parma Recent Developments
8.8 Noven Pharmaceuticals
8.8.1 Noven Pharmaceuticals Comapny Information
8.8.2 Noven Pharmaceuticals Business Overview
8.8.3 Noven Pharmaceuticals ADHD Medication Revenue and Gross Margin (2020-2025)
8.8.4 Noven Pharmaceuticals ADHD Medication Product Portfolio
8.8.5 Noven Pharmaceuticals Recent Developments
8.9 Neos Therapeutics
8.9.1 Neos Therapeutics Comapny Information
8.9.2 Neos Therapeutics Business Overview
8.9.3 Neos Therapeutics ADHD Medication Revenue and Gross Margin (2020-2025)
8.9.4 Neos Therapeutics ADHD Medication Product Portfolio
8.9.5 Neos Therapeutics Recent Developments
8.10 Mallinckrodt
8.10.1 Mallinckrodt Comapny Information
8.10.2 Mallinckrodt Business Overview
8.10.3 Mallinckrodt ADHD Medication Revenue and Gross Margin (2020-2025)
8.10.4 Mallinckrodt ADHD Medication Product Portfolio
8.10.5 Mallinckrodt Recent Developments
8.11 Amneal Pharmaceuticals
8.11.1 Amneal Pharmaceuticals Comapny Information
8.11.2 Amneal Pharmaceuticals Business Overview
8.11.3 Amneal Pharmaceuticals ADHD Medication Revenue and Gross Margin (2020-2025)
8.11.4 Amneal Pharmaceuticals ADHD Medication Product Portfolio
8.11.5 Amneal Pharmaceuticals Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.